MetaCap

Nuwellis Inc. (NUWE)

NASDAQ: NUWEHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD

3.41-0.40 (-10.50%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NUWE stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
$3,609.63
52-week range
2.52 – 1,556.10
Day range
3.27 – 3.78
Volume / Avg
8.99K / 829.19K
Beta
—

52-week range

$2.52$1,556.10

NUWE stock today

Shares of Nuwellis (NUWE) finished lower on Nov 20 at $3.41, a drop of 10.50% or $0.40 per share, versus the S&P 500's 3.70% decline. Trading was light, with 8.99K shares changing hands, about 1% of the average daily volume. Shares are 99.8% below their 52-week high of $1,556.10 and 35.3% above the 52-week low of $2.52, near the bottom of the past year's range.

Nuwellis trades at 0.0x its trailing twelve-month earnings per share of $3,609.63.

Summary generated from market data by MetaCap's automated system. Methodology

About Nuwellis

Company profile

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients. The company was formerly known as CHF Solutions, Inc.

Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
CEO
Mr. Michael Kendrick McCormick
Headquarters
Eden Prairie, MN
Employees
38

Financial highlights

Full financials

In fiscal 2025, Nuwellis generated $8.3 million in revenue, down 5.4% from fiscal 2024, its first annual decline since 2024. Nuwellis reported a net loss of $17.5 million, compared with a loss of $11.2 million a year earlier. Gross margin was 62.0% (down from 64.9%) and operating margin -134.3%.

Nuwellis annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$8.27M$8.74M$8.86M$8.54M$7.92M
Growth-5.38%-1.40%+3.76%+7.85%+6.45%
Net income$-17.52M$-11.16M$-20.21M$-14.53M$-19.55M
EPS (diluted)$-25.39$-353.30$-360.06$-83.55$-285.36

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-5.81 vs —

NUWE news

All NUWE news

Nuwellis peers

Health Care sector
NUWE peer companies
CompanyPrice% ChgMarket capCompare
NXLNexalin Technology Inc.1.38-2.13%$1.71Mvs NUWE
VBIOValion Bio Inc.0.4806-10.98%$1.04Mvs NUWE
NDRAENDRA Life Sciences Inc.3.58-3.38%$5.36Mvs NUWE
IRIXIRIDEX Corporation0.4449-4.59%$7.92Mvs NUWE
ITOCiTonic Holdings Ltd Class A1.59+6.00%$11.63Mvs NUWE
QTIQT Imaging Holdings Inc.1.92+2.67%$28.21Mvs NUWE
ECORelectroCore Inc.4.42-8.87%$40.78Mvs NUWE
POCIPrecision Optics Corporation Inc.4.12+1.41%$45.30Mvs NUWE

Indexes, lists and sector

Nuwellis stock FAQ

What is Nuwellis's stock price today?

NUWE last traded at $3.41 as of Nov 20, 4:00 PM EST, down 10.50% on the day. Prices are delayed at least 15 minutes.

Does Nuwellis pay a dividend?

No. Nuwellis does not currently pay a regular cash dividend.

What is NUWE's P/E ratio?

NUWE trades at a trailing P/E ratio of 0.00.

Who is Nuwellis's CEO?

Mr. Michael Kendrick McCormick is the chief executive officer of Nuwellis Inc., which has about 38 employees.

Has NUWE ever split its stock?

Yes. The most recent NUWE stock split was a 1-for-9 split on Oct 27, 2026.

What is the NUWE 52-week high?

The 52-week high for NUWE is $1,556.10 and the 52-week low is $2.52. The stock is currently 99.8% below its high.

Compare NUWE